Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 12:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Herpes Simplex Oral Clear all
Completed Phase 4 Interventional Results available

VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2

NCT00306293
View directory record Official record
Conditions
Herpes Labialis
Interventions
valacyclovir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
18
States / cities
Anaheim, California • Carmichael, California • Fair Oaks, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Jul 24, 2026, 12:37 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis

NCT00361881
View directory record Official record
Conditions
Herpes Labialis
Interventions
ME-609, acyclovir in ME-609 vehicle, Vehicle
Drug
Lead sponsor
Medivir
Industry
Eligibility
18 Years and older
Enrollment
1,443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2008 · Synced Jul 24, 2026, 12:37 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

300 Antibody Diagnostic Test Kit

NCT01646411
View directory record Official record
Conditions
Acute Bacterial Infections, Acute Viral Infections
Interventions
Not listed
Lead sponsor
The Plasma Source
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Southampton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Jul 24, 2026, 12:37 AM EDT
Completed Phase 3 Interventional

A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems

NCT00002315
View directory record Official record
Conditions
HIV Infections, Chickenpox
Interventions
Netivudine, Acyclovir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
25
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 24, 2026, 12:37 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Viral Infections in Healthy and Immunocompromised Hosts

NCT01306084
View directory record Official record
Conditions
Anogenital Herpes, COVID-19, Herpes Labialis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 24, 2026, 12:37 AM EDT
Terminated Phase 2 Interventional Results available

A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis

NCT00913692
View directory record Official record
Conditions
Herpes Labialis, Herpes Simplex Virus
Interventions
Glutamine, Glycine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Jul 24, 2026, 12:37 AM EDT
Completed Phase 3 Interventional

Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Limited to Skin, Eyes, and Mouth

NCT00006135
View directory record Official record
Conditions
Herpes Simplex
Interventions
acyclovir
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years to 28 Days
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
25
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 24, 2026, 12:37 AM EDT
Completed Phase 3 Interventional Results available

Acyclovir Herpes Simplex Virus (HSV) Skin, Eye, and Mouth

NCT00031447
View directory record Official record
Conditions
Herpes Simplex
Interventions
Acyclovir, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 28 Days
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
27
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced Jul 24, 2026, 12:37 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

30-Day Trial of Oral Valtrex or Valtrex Plus Aspirin on Shedding of HSV DNA in Tears and Saliva of Volunteers

NCT00587496
View directory record Official record
Conditions
Herpes Simplex
Interventions
valacyclovir hydrochloride, placebo, valacyclovir plus aspirin
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
20 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 6, 2008 · Synced Jul 24, 2026, 12:37 AM EDT
Completed Phase 1 Interventional Results available

Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis

NCT01971385
View directory record Official record
Conditions
Herpes Labialis
Interventions
Squaric Acid solution, Placebo solution
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2017 · Synced Jul 24, 2026, 12:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis

NCT01321359
View directory record Official record
Conditions
Recurrent Herpes Simplex Labialis
Interventions
Vehicle versus NB-001
Drug
Lead sponsor
NanoBio Corporation
Industry
Eligibility
18 Years and older
Enrollment
907 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
35
States / cities
Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Jul 24, 2026, 12:37 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for the Treatment of Cold Sores

NCT01985321
View directory record Official record
Conditions
Recurrent Herpes Labialis
Interventions
ethanol/glycolic acid solution, Placebo/Ethanol
Drug
Lead sponsor
Topical Remedy
Industry
Eligibility
18 Years to 75 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
8
States / cities
Santa Rosa, California • Pinellas Park, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Jul 24, 2026, 12:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Investigation Into the Efficacy of Herpecin L at Reducing the Frequency and Severity of Cold Sores

NCT05796635
View directory record Official record
Conditions
Cold Sores
Interventions
Herpecin L
Other
Lead sponsor
Focus Consumer Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2023 · Synced Jul 24, 2026, 12:37 AM EDT
Completed No phase listed Observational

Structure of the Herpes Simplex Virus Receptor

NCT00001648
View directory record Official record
Conditions
Encephalitis, Herpes Simplex, Keratitis, Mouth Disease, Skin Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 24, 2026, 12:37 AM EDT
Completed Phase 2 Interventional Results available

EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions

NCT04893577
View directory record Official record
Conditions
Herpes Simplex Oral
Interventions
EDTA, Abreva
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jul 24, 2026, 12:37 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis

NCT00878072
View directory record Official record
Conditions
Herpes Labialis
Interventions
Famciclovir
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 18 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
San Diego, California • Chicago, Illinois • Evansville, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Jul 24, 2026, 12:37 AM EDT
Completed Phase 1 Interventional Results available

Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1)

NCT03661541
View directory record Official record
Conditions
HSV, Herpes Labialis
Interventions
Squaric Acid Dibutyl Ester
Drug
Lead sponsor
Squarex, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jul 24, 2026, 12:37 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Cold Sore Treatments on Ultra Violet (UV) Induced Cold Sores

NCT01902303
View directory record Official record
Conditions
Oral Herpes Simplex
Interventions
Matching Placebo, BTL-TML-HSV
Drug
Lead sponsor
Beech Tree Labs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
St. Petersburg, Florida • Cincinnati, Ohio • Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Jul 24, 2026, 12:37 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection

NCT00448227
View directory record Official record
Conditions
Herpes Simplex
Interventions
famciclovir
Drug
Lead sponsor
Novartis
Industry
Eligibility
1 Month to 1 Year
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2011 · Synced Jul 24, 2026, 12:37 AM EDT
Completed Phase 3 Interventional

Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection

NCT00098046
View directory record Official record
Conditions
Chickenpox, Herpes Zoster
Interventions
famciclovir
Drug
Lead sponsor
Novartis
Industry
Eligibility
1 Year to 12 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2007 · Synced Jul 24, 2026, 12:37 AM EDT
Not listed Phase 3 Interventional

NB-001 Treatment of Recurrent Herpes Labialis

NCT01695187
View directory record Official record
Conditions
Herpes Labialis
Interventions
NB-001 (0.3%), Placebo
Drug
Lead sponsor
NanoBio Corporation
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Chandler, Arizona • Tucson, Arizona • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced Jul 24, 2026, 12:37 AM EDT
Not listed Phase 2 Interventional

Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)

NCT00652184
View directory record Official record
Conditions
Herpes Zoster, Postherpetic Neuralgia
Interventions
ARYS-01 (sorivudine) cream 3% or placebo cream, placebo, valaciclovir
Drug
Lead sponsor
aRigen Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Beverly Hills, California • Encino, California • Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2008 · Synced Jul 24, 2026, 12:37 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis

NCT00297011
View directory record Official record
Conditions
Herpes Labialis
Interventions
valacyclovir+clobetasol gel
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 5, 2008 · Synced Jul 24, 2026, 12:37 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis

NCT00230867
View directory record Official record
Conditions
Herpes Labialis
Interventions
iontophoretic acyclovir
Device
Lead sponsor
Transport Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
26
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2006 · Synced Jul 24, 2026, 12:37 AM EDT